GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent ...

GSK is moving out of its 635K SF footprint at 14200 Shady Grove Road, where it is the sole tenant, just before its lease ...

GSK plans to buy back $2.50 billion in shares ... It also aims to increase research-and-development spending in line with sales. Chief Executive Emma Walmsley said in a media call that the company ...

GSK'227 targets B7-H3 ... In December, we presented overall survival data from the DREAMM-7 second-line multiple myeloma study at ASH, and the data demonstrated a statistically significant ...

GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...

GSK's annual revenues were held back weak vaccines sales, but shares in the pharma giant jumped on Wednesday after the ...

Ten companies traded in line with the broader market sentiment ... British pharmaceutical giant GSK plc (NYSE:GSK) saw its share prices on Wednesday rise by 8.21 percent to finish at $37.70 ...

Vaccine sales declined 12%. GSK’s Specialty Medicines Drive Top Line HIV sales rose 14% during the quarter, driven by strong patient demand for the company’s two-drug regimens — Dovato and J ...